β adrenergic receptor

β-adrenergic receptors (β-ARs) are G protein-coupled receptors that regulate cardiac homeostasis, including myocyte contraction, heart rate, and coronary blood flow^[1]. Mechanistically, β-AR signaling couples receptor activation to Gs proteins, adenylyl cyclase, cAMP, protein kinase A, and downstream effectors, while GRKs phosphorylate agonist-occupied receptors and initiate desensitization^[1][2]. In heart failure research, chronic β-adrenergic stimulation associates with increased morbidity and mortality, whereas β-blockade is part of standard care and distal β-AR-G protein-adenylyl cyclase mechanisms remain therapeutic targets^[2]. Compared with related isoforms, β₂-adrenergic receptors show cardioprotective activity in doxorubicin cardiomyopathy models, whereas β₁-adrenergic receptors mediate at least some acute anthracycline cardiotoxicity^[3]. In chronic volume overload, β₁-blockade with metoprolol associates with myocardial β₃AR/NO-cGMP coupling, supporting isoform-specific signaling in cardiac benefit^[4]. In neuroinflammation models, β-blockers potentiated peripheral inflammation and CNS inflammation in amyloid pathology models, while β-adrenergic agonists inhibited synaptosome phagocytosis in primary microglia cultures^[5]. For experimental applications, agonists, partial agonists, neutral antagonists, and inverse agonists provide tools to classify β₂-adrenergic receptor conformational states and receptor signaling outcomes^[6].